1
|
Xu B, Zhang L, Wu D, Qi Z, Cao J, Li W, Fan L, Shi Y, Wu Y, Li G. CuO nanoparticles elicit intestinal immunotoxicity in zebrafish based on intestinal microbiota dysbiosis. Food Funct 2024; 15:7619-7630. [PMID: 38940701 DOI: 10.1039/d4fo01032a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2024]
Abstract
Copper II oxide nanoparticles (CuO NPs), a kind of widely used nanomaterial, have been detected in food and the environment, which has aroused widespread public concern. Recently, increasing data have suggested that intestinal microecology is closely related to immune homeostasis. However, the intestinal immunotoxicity induced by CuO NPs through intestinal microbiota is still unknown. Therefore, in this study, zebrafish were exposed to CuO NPs to explore intestinal immunotoxicity by evaluating physiological indicators, intestinal tissue injury, antioxidant enzyme activities, gene expression of immune factors, and changes in intestinal microbiota and its metabolites (short-chain fatty acids (SCFAs) and lipopolysaccharides (LPS)). The results revealed that the intestinal immunotoxicity of CuO NPs was mediated by the impact on intestinal microbiota and its metabolite levels. Specifically, changes were observed in the abundance of microbes that participated in the metabolism of SCFAs and LPS. The reduction in acetic acid, propionic acid and valeric acid upregulated GPR84 expression, and the decline in LPS levels further resulted in the suppression of the key immune regulatory pathways TLR4/MyD88/NF-κB, ultimately leading to intestinal immunotoxicity. This study would provide a scientific basis for the risk assessment of CuO NPs and a new perspective for research on the immunotoxicity of nanoparticles.
Collapse
Affiliation(s)
- Bufan Xu
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Luyao Zhang
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Di Wu
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
- Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast, BT9 5DL, UK
| | - Zihe Qi
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Juanjuan Cao
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Wenrui Li
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Lihua Fan
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Yiheng Shi
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| | - Yongning Wu
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
- NHC Key Laboratory of Food Safety Risk Assessment, Food Safety Research Unit (2019RU014) of Chinese Academy of Medical Science, China National Center for Food Safety Risk Assessment, Beijing 100021, China
| | - Guoliang Li
- School of Food Science and Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.
| |
Collapse
|
2
|
Donovan C, Thorpe AE, Gomez HM, Carroll OR, Feng M, Bai X, Chen H, Horvat JC, Oliver BGG, Kim RY. The GPR84 Antagonist GLPG1205 Reduces Features of Disease in Experimental Severe Asthma. Am J Respir Cell Mol Biol 2024; 70:424-427. [PMID: 38690993 DOI: 10.1165/rcmb.2023-0221le] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2024] Open
Affiliation(s)
- Chantal Donovan
- University of Technology Sydney Sydney, New South Wales, Australia
- The University of Newcastle Newcastle, New South Wales, Australia
- Woolcock Institute of Medical Research Glebe, New South Wales, Australia
| | - Andrew E Thorpe
- University of Technology Sydney Sydney, New South Wales, Australia
- Woolcock Institute of Medical Research Glebe, New South Wales, Australia
| | - Henry M Gomez
- The University of Newcastle Newcastle, New South Wales, Australia
| | - Olivia R Carroll
- The University of Newcastle Newcastle, New South Wales, Australia
| | - Min Feng
- University of Technology Sydney Sydney, New South Wales, Australia
| | - Xu Bai
- University of Technology Sydney Sydney, New South Wales, Australia
| | - Hui Chen
- University of Technology Sydney Sydney, New South Wales, Australia
| | - Jay C Horvat
- The University of Newcastle Newcastle, New South Wales, Australia
| | - Brian G G Oliver
- University of Technology Sydney Sydney, New South Wales, Australia
- Woolcock Institute of Medical Research Glebe, New South Wales, Australia
| | - Richard Y Kim
- University of Technology Sydney Sydney, New South Wales, Australia
- The University of Newcastle Newcastle, New South Wales, Australia
- Woolcock Institute of Medical Research Glebe, New South Wales, Australia
| |
Collapse
|
3
|
Milligan G. Editorial for GPR84 pharmacology. Br J Pharmacol 2024; 181:1497-1499. [PMID: 38456201 DOI: 10.1111/bph.16340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2024] Open
Abstract
LINKED ARTICLES This article is part of a themed issue GPR84 Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.10/issuetoc.
Collapse
Affiliation(s)
- Graeme Milligan
- Centre for Translational Pharmacology, School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| |
Collapse
|
4
|
Yang X, Zhang W, Wang L, Zhao Y, Wei W. Metabolite-sensing GPCRs in rheumatoid arthritis. Trends Pharmacol Sci 2024; 45:118-133. [PMID: 38182481 DOI: 10.1016/j.tips.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 12/05/2023] [Accepted: 12/12/2023] [Indexed: 01/07/2024]
Abstract
Persistent inflammation in damaged joints results in metabolic dysregulation of the synovial microenvironment, causing pathogenic alteration of cell activity in rheumatoid arthritis (RA). Recently, the role of metabolite and metabolite-sensing G protein-coupled receptors (GPCRs) in the RA-related inflammatory immune response (IIR) has become a focus of research attention. These GPCRs participate in the progression of RA by modulating immune cell activation, migration, and inflammatory responses. Here, we discuss recent evidence implicating metabolic dysregulation in RA pathogenesis, focusing on the connection between RA-related IIR and GPCR signals originating from the synovial joint and gut. Furthermore, we discuss future directions for targeting metabolite-sensing GPCRs for therapeutic benefit, emphasizing the importance of identifying endogenous ligands and investigating the various transduction mechanisms involved.
Collapse
Affiliation(s)
- Xuezhi Yang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China
| | - Wankang Zhang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China
| | - Luping Wang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China
| | - Yingjie Zhao
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
| | - Wei Wei
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, China.
| |
Collapse
|